ATHE
Alterity Therapeutics Limited·Healthcare
3.72
3.381%(−0.13)
Market ClosedLast Updated: — ET
52W L: $2.6652W H: $7.00
ATHE NEWS
globenewswire.com
Mar 30
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Alignment reached on key elements of ATH434 Phase 3 development program Alignment reached on key elements of ATH434 Phase 3 development program
defenseworld.net
Mar 26
Alterity Therapeutics Conference: ATH434 Phase II MSA Data, FDA Talks Next, Phase III Set
Alterity Therapeutics (NASDAQ: ATHE) outlined its development strategy for lead drug candidate ATH434, highlighting positive Phase II data in multiple system atrophy (MSA), planned regulatory interactions with the U.S. Food and Drug Administration (FDA), and preparations to move into a global Phase III program. Company focus and the unmet need in MSA In the presentation, the
defenseworld.net
Mar 15
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Up 69.4% in February
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) saw a large growth in short interest during the month of February. As of February 27th, there was short interest totaling 19,055 shares, a growth of 69.4% from the February 12th total of 11,249 shares. Currently, 0.4% of the company's stock are short sold.
globenewswire.com
Mar 9
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in the Bell Potter Healthcare Horizons Summit taking place 12-13 March 2026 in Sorrento, Australia.
globenewswire.com
Mar 2
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies –
defenseworld.net
Feb 14
Head-To-Head Contrast: Alterity Therapeutics (NASDAQ:ATHE) & Athira Pharma (NASDAQ:ATHA)
Athira Pharma (NASDAQ: ATHA - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership. Risk and Volatility Athira Pharma has a
